Posttraumatic Stress Disorder
Conditions
Keywords
Posttraumatic Stress Disorder, Cognitive Processing Therapy, Active Duty Military
Brief summary
The primary goal of this study is to improve the overall efficacy of cognitive processing therapy-cognitive-only version (CPT-C) in a sample of 130 active-duty service members through a variable length treatment.
Detailed description
The primary goal of this study is to improve the overall efficacy of cognitive processing therapy-cognitive-only version (CPT-C) in a sample of 130 active-duty service members through a variable length treatment. The study seeks to determine if some service members would benefit from a longer or shorter dose of treatment (4-24 sessions), and to identify which individuals are likely to require more, less, or the standard number of treatment sessions to reach good end-state functioning. Predictors of length of therapy and treatment outcome will be examined. Specifically, we will evaluate factors related to internalizing/externalizing traits, cognitive flexibility, inability to inhibit dysfunctional cognitions, and readiness to change as they are related to the number of treatment sessions required to treat patients to the point of good end-state functioning. Additional outcomes including alcohol use, psychosocial functioning, physical health, and sleep also will be evaluated.
Interventions
BEHAVIORALCognitive Processing Therapy-Cognitive Only
Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
Sponsors
Boston VA Research Institute, Inc.
The University of Texas Health Science Center at San Antonio
STRONG STAR Consortium
Duke University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Variable length Cognitive Processing Therapy
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult male and female combat veterans who deployed in support of combat operations following 9/11 * Diagnosis of PTSD determined by a Clinician-Administered Posttraumatic Stress Scale (CAPS-5) * Speak and read English
Exclusion criteria
* Current suicide or homicide risk meriting crisis intervention. * Active psychosis. * Moderate to severe brain damage (as determined by the inability to comprehend the baseline screening questionnaires). * Local availability of fewer than 5 months * Late-phase Med Board status, awaiting percentages * Undergoing a chapter
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in PTSD symptoms as measured by thePosttraumatic Stress Disorder Checklist-5 (PCL-5) | Pretreatment, weekly during treatment, 4 weeks, 12 weeks, and 24 weeks posttreatment | PCL-5 measures symptoms of posttraumatic stress disorder in response to a specific stressor. |
| Change from baseline in PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5) | Pretreatment, weekly during treatment, 4 weeks, 12 weeks, and 24 weeks posttreatment | is an updated version of the gold standard CAPS designed to assess the criteria for PTSD as defined by the DSM-5 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in depressive symptoms as measured by the Patient Health Questionnaire-9 | Pretreatment, weekly during treatment, 4 weeks, 12 weeks, and 24 weeks posttreatment | The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms (Kroenke, Spitzer, & Williams, 2001). It consists of 9 items that assess both affective and somatic symptoms related to depression and depressive disorders; these 9 items correspond to the diagnostic criteria for DSM MDD. Respondents rate the frequency with which they have been bothered by depressive symptoms within the past two weeks on a scale ranging from 0 (not at all) to 3 (nearly every day). Scores on all items are summed to obtain a total severity score. |
Countries
United States
Outcome results
None listed